For the quarter ending 2025-09-30, SLN had $40,398K increase in cash & cash equivalents over the period. -$10,894K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -20,958 | -55,884 |
| Depreciation expense | 81 | 154 |
| Amortization expense | 75 | 132 |
| Share-based compensation expense | 2,535 | 5,625 |
| Net foreign exchange impacts | 918 | -11,710 |
| Other income, net | 770 | 1,830 |
| Income tax expense | 1 | 10 |
| Decrease/(increase) in trade receivables | -62 | -932 |
| Decrease/(increase) in other current assets | -5,331 | -2,426 |
| Decrease in r&d benefit receivable | 2,492 | -6,343 |
| Decrease in other long-term assets | -3,387 | -14 |
| (decrease)/increase in trade and other payables | 2,883 | -3,385 |
| Decrease in contract liabilities | -88 | -214 |
| Decrease in operating lease liabilities | -20 | -126 |
| Net cash provided by/(used in) operations | -10,891 | -34,093 |
| Redemption of term deposits | 71,478 | 26,558 |
| Purchase of term deposits | 20,186 | 72,449 |
| Purchase of property, plant and equipment | 3 | 52 |
| Net cash provided by/(used in) investing activities | 51,289 | -45,943 |
| Proceeds from issue of ordinary shares | 0 | 15 |
| Net cash provided by financing activities | 0 | 15 |
| (decrease)/increase in cash and cash equivalents | 40,398 | -80,021 |
| Cash and cash equivalents at beginning of period | 121,330 | - |
| Effect of exchange rate changes on cash | 324 | - |
| Cash and cash equivalents at end of period | 82,031 | - |
Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN)